EXACT Therapeutics Past Earnings Performance
Past criteria checks 0/6
EXACT Therapeutics's earnings have been declining at an average annual rate of -13.7%, while the Biotechs industry saw earnings growing at 13.6% annually. Revenues have been declining at an average rate of 108.7% per year.
Key information
-13.7%
Earnings growth rate
-9.2%
EPS growth rate
| Biotechs Industry Growth | 20.9% |
| Revenue growth rate | -108.7% |
| Return on equity | -107.2% |
| Net Margin | -1,084,201.2% |
| Next Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn Situation
Aug 09
Is EXACT Therapeutics (OB:EXTX) In A Good Position To Invest In Growth?
Apr 20We Think EXACT Therapeutics (OB:EXTX) Can Afford To Drive Business Growth
Sep 07We're Hopeful That EXACT Therapeutics (OB:EXTX) Will Use Its Cash Wisely
May 06Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn Situation
Dec 30Companies Like EXACT Therapeutics (OB:EXTX) Are In A Position To Invest In Growth
Sep 15EXACT Therapeutics (OB:EXTX) Is In A Good Position To Deliver On Growth Plans
Jan 31We Think EXACT Therapeutics (OB:EXTX) Can Afford To Drive Business Growth
Aug 21We're Not Very Worried About EXACT Therapeutics' (OB:EXTX) Cash Burn Rate
May 21Revenue & Expenses Breakdown
How EXACT Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -48 | 23 | 0 |
| 30 Sep 23 | 0 | -42 | 21 | 0 |
| 30 Jun 23 | 0 | -36 | 20 | 0 |
| 31 Mar 23 | 0 | -38 | 17 | 0 |
| 31 Dec 22 | 0 | -40 | 15 | 0 |
| 30 Sep 22 | 0 | -45 | 11 | 0 |
| 30 Jun 22 | 0 | -49 | 7 | 0 |
| 31 Mar 22 | 0 | -54 | 13 | 0 |
| 31 Dec 21 | 0 | -59 | 19 | 0 |
| 30 Sep 21 | 0 | -58 | 23 | 0 |
| 30 Jun 21 | 0 | -58 | 27 | 0 |
| 31 Mar 21 | 0 | -46 | 21 | 0 |
| 31 Dec 20 | 0 | -33 | 15 | 0 |
| 31 Dec 19 | 0 | -15 | 6 | 0 |
| 31 Dec 18 | 6 | -8 | 6 | 0 |
| 31 Dec 17 | 8 | -5 | 4 | 0 |
Quality Earnings: EXTX is currently unprofitable.
Growing Profit Margin: EXTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EXTX is unprofitable, and losses have increased over the past 5 years at a rate of 13.7% per year.
Accelerating Growth: Unable to compare EXTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EXTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-17.8%).
Return on Equity
High ROE: EXTX has a negative Return on Equity (-107.17%), as it is currently unprofitable.